A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
[en] In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin) with a reference preparation containing 30 microg ethinylestradiol and 150 microg desogestrel (Marvelon) on variables of carbohydrate metabolism by means of oral glucose tolerance tests at baseline and in the 6th and 13th treatment cycle. The mean levels of fasting glucose and insulin were similar at baseline and after 13 treatment cycles, whereas C-peptide and free fatty acid levels decreased slightly in both groups. All blood glucose and insulin values measured in the oral glucose tolerance tests were within normal ranges, despite a slight increase in the mean areas under the curves of 0-3 h [AUCs (0-3 h)] of both variables from baseline to treatment cycle 13. Differences between both treatments were not statistically significant. The mean AUCs (0-3 h) for C-peptide were not markedly changed in any treatment group. Free fatty acid levels decreased by 42% in the drospirenone group and increased by 48.9% in the desogestrel group, in terms of means of individual changes. Both preparations were well tolerated and equally efficacious regarding contraception and cycle control. The mean body weight was slightly decreased in most cycles during treatment with the drospirenone combination, as compared to baseline, while it was slightly increased versus baseline in all cycles during treatment with the desogestrel combination. The combination with drospirenone had less impact on blood pressure than the combination with desogestrel. In conclusion, Yasmin, a combined low-dose oral contraceptive with 30 microg ethinylestradiol and 3 mg of the novel progestogen drospirenone, as well as the reference Marvelon, containing 30 microg ethinylestradiol and 150 microg desogestrel had little impact on carbohydrate metabolism when used for 1 year. The observed changes were small and not suggestive of a clinically relevant deterioration of carbohydrate metabolism.
Disciplines :
Endocrinology, metabolism & nutrition Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Gaspard, Ulysse ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Endrikat, J.
Buicu, C.
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Gerlinger, C.
Heithecker, R.
Language :
English
Title :
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for proprietary medicinal products (CPMP). Note for guidance on clinical investigation of steroid contraceptives in women. 17 February 2000 CPMP/EWP/519/98.
Crook D., Godsland I.F., Worthington M., et al. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol. 169:1993;1183-1189.
Watanabe R.M., Azen C.G., Roy S., Perlman J.A., Bergman R.N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab. 79:1994;1277-1283.
Eschwege E., Fontbonne A., Simon D., et al. Oral contraceptives, insulin resistance and ischemic vascular disease. Int J Gynecol Obstet. 31:1990;263-269.
Laakso M. Hyperglycaemia as a cardiovascular risk factor. Int Diabetes Monitor. 12:(5):2000;1-5.
Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 22:1999;233-240.
Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria . Lancet. 354:1999;617-621.
Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol. 7:1996;217-226.
Reaven G.M. Role of insulin resistance in human disease (Syndrome X) an expanded definition . Annu Rev Med. 60:1993;664-667.
Skouby S.O. The rationale for a wider range of progestogens. Climacteric. 3:2000;14-20.
Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models . Contraception. 51:1995;99-110.
Foidart J.M., Oelkers W., Heithecker R. Drospirenone a novel progestogen with antimineralocorticoid and antiandrogenic activity: a major breakthrough in tomorrow's oral contraception . Gynecol Snapshot. 3:(2):1995;13-17.
Fuhrmann U., Krattenmacher R., Slater E.P., Fritzemeier K.-H. The novel progestin drospirenone and its natural counterpart progesterone biochemical profile and antiandrogenic potential . Contraception. 54:1996;243-251.
Huber J., Foidart J.M., Wuttke W., et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 5:2000;25-34.
Parsey K.S., Pong A. An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 61:2000;105-111.
Oelkers W., Foidart J.M., Dombrovich N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab. 80:1995;1816-1821.
Hales C.N., Randle P.J. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 88:1963;137-146.
Heding L.G. Radioimmunological determination of human C-peptide in serum. Diabetologia. 11:1975;541-548.
Okabe J., Uji Y., Nagashima K., Noma A. Enzymic determination of free fatty acids in serum. Clin Chem. 26:1980;1540-1543.
Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197.
Jandrain B.J., Humblet D.M., Jaminet C.B., Scheen A.J., Gaspard U.J., Lefebvre P.J. Effects of ethinylestradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load a one-year randomized, prospective, comparative trial . Am J Obstet Gynecol. 163:1990;378-381.
Si S., Jun-kang C., Pei-juan Y., et al. A cross-over study of three oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel. Contraception. 45:1992;523-532.
Gaspard U.J., Demeyer F., Jaminet C.B., Scheen A.J., Lefebvre P.J. Influence of two low-dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use. Gynecol Endocrinol. 10:(Suppl 2):1996;179-181.
Godsland I.F., Crook D., Davenport M., Wynn V. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception. 52:1995;143-149.
Gaspard U.J. Metabolic effects of oral contraceptives. Am J Obstet Gynecol. 157:1987;1029-1041.
Straznicky N.E., Barrington V.E., Branley P., Louis W.J. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women. J Hypertens. 16:1998;357-368.
Godsland I.F. Effects on carbohydrate metabolism. Fraser I.S., Jansen R.P.S., Lobo R.A., Whitehead M.I. Estrogens and progestogens in clinical practice. 1998;773-785 Churchill Livingstone, London, Edinburgh, New York, Philadelphia, San Francisco, Sydney.
Godsland I.F., Crook D., Worthington M., Proudler A.J., Felton C., et al. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism. Contraception. 48:1993;217-221.
Singh B.M., Nattrass M. Use of combined oral contraceptive preparations alters the insulin sensitivity of fatty acid and ketone metabolism. Clin Endocrinol (Oxford). 30:1989;561-570.
Jarret R.J., Graver H.J. Changes in oral glucose tolerance during the menstrual cycle. Br Med J. 2:1968;528-529.
Chasan Taber L., Willett W.C., Stampfer M.J., Hunter D.J., Colditz G.A., Spiegelmann D., Manson J.E. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care. 20:1997;330-335.
Russel-Briefel R., Ezzati T.M., Perlman J.A., Murphy R.S. Impaired glucose tolerance in women using oral contraceptives United States 1976-1980 . J Chronic Dis. 40:1987;3-11.
Scheen A.J., Jandrain B.J., Humblet D.M., Jaminet C.B., Gaspard U.J., Lefebvre P.J. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinylestradiol and cyproterone acetate on glucose and insulin metabolism. Fertil Steril. 59:1993;797-802.
